Oncology Analytics Secures $21 Million Series B Funding to Expand Oncology Benefits Management Capabilities

Recently, VCBeat (WeChat Official Account: vcbeat) learned from foreign media reports that U.S. oncology management company Oncology Analytics (OA) announced the completion of its $21 million Series B financing round. The round was led by Oak HC/FT, with participation from new investors McKesson Ventures, BlueCross BlueShield Venture Partners, and Sandbox Advantage Fund. Following the completion of this financing, the company plans to use the funds to expand its oncology benefit management capabilities and accelerate strategic investments in data analytics, data science, and innovative digital health technologies.

OA, founded in 2009 and headquartered in Florida, USA, is an oncology management company and a leading provider of innovative oncology management services in the United States. The clinical decision support network system developed by OA collaborates with teams of clinical oncology experts to provide real-time professional expertise to oncologists, thereby ensuring that patients receive accurate and effective treatment while helping them avoid additional costs associated with inadequate initial therapy.

Image from Unsplash official website

The company has developed a technology-driven utilization management program specifically for oncology, primarily serving health plans and cancer patients. In the United States and Puerto Rico, this program has been used by physicians to support more than 3.5 million health plan members. To date, the company’s clinical decision support network system covers more than 6,000 oncology treatment regimens for all cancer types and stages, including chemotherapy, radiation therapy, precision medicine, targeted therapy, and supportive care.

OA has experienced rapid growth in recent years, achieving significant success in chemotherapy decision support services. Today, the company has expanded its business into all aspects of oncology, ranging from basic diagnostic examinations to specialized genetic testing, with the aim of providing optimal treatment plans tailored to each patient’s specific clinical needs.

OA also announced that, as part of this financing round, healthcare investor Annie Lamont, Managing Partner of Oak HC/FT, venture capital partner, renowned bioethicist, and oncologist Ezekiel J. “Zeke” Emanuel will join the OA Board of Directors.

Oak HC/FT is a venture capital firm focused on investing in the healthcare information services and financial services sectors, primarily targeting companies at early-stage, late-stage, and private equity stages. Oak HC/FT is committed to driving transformation in its portfolio companies by providing strategic advisory services and active board participation to entrepreneurs and businesses. Over the past decade, Oak HC/FT has invested in approximately 20 companies, six of which have achieved valuations exceeding $1 billion.

McKesson is a venture capital firm that primarily invests in innovative enterprises within the healthcare sector. Leveraging its expertise, McKesson supports leading healthcare startups through dedicated strategic venture funds, helping innovators build and scale their businesses, thereby driving sustainable development in the healthcare industry.

BlueCross BlueShield Venture Partners is a corporate venture capital fund sponsored by the BlueCross and BlueShield Association. It manages three funds with over $575 million in assets, primarily investing in startups that have strategic relevance to the BCBS (BlueCross and BlueShield) plans. The firm introduces its portfolio companies into the Blue Plans, providing growth opportunities for invested companies to achieve mutual benefits.

Sandbox is the exclusive investment management services provider for Blue Cross Blue Shield Venture Partners, primarily supporting emerging innovative companies and health plans. The fund mainly invests in companies that align with its BCBS plan and investor strategies.